Tandem Diabetes Care Shares Rise 12% Following FDA Clearance of Tubeless Mobi System
Tandem Diabetes Care (TNDM) saw its stock price surge by 12% on Friday, reaching $19.62 per share, following the announcement that the FDA has granted 510(k) clearance for a tubeless version of its Mobi system. The newly cleared device is an automated insulin-delivery system designed to operate without tubing, representing a significant technological advancement for the company's product lineup. This regulatory milestone is expected to strengthen Tandem's position in the diabetes management market.
Tickers: $TNDM
Topics: FDA clearance insulin delivery medical devices stock price movement
Read the full article at Seeking Alpha
Part of the story TANDEM DIABETES CARE INC - 8-K Filing (2 articles)